Endocyte Inc (ECYT) 2.98 $ECYT Endocyte to Present at

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 9:03 AM

Endocyte Inc (ECYT) 2.98 $ECYT

Endocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 09, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 16, at 12:45 p.m. EDT. The conference will be held at the Le Parker Meridien Hotel in New York.
ECYT: 2.98 (-0.04)

Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 4:31AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.98 (-0.04), GERN: 1.99 (+0.11), LGND: 115.54 (+0.46), CORT: 5.76 (+0.01)

Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:55AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 25 cents per share, narrower than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.98 (-0.04), GERN: 1.99 (+0.11), CORT: 5.76 (+0.01), ANIK: 47.37 (unch)

Endocyte Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
- Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 -
ECYT: 2.98 (-0.04)

Endocyte Announces Second Quarter 2016 Earnings Conference Call
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Thursday, August 4th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update.
ECYT: 2.98 (-0.04)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 26.15 (+0.27), ECYT: 2.98 (-0.04), IRWD: 14.92 (-0.13), EXEL: 13.69 (+0.14)

Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 26, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2016, in Chicago.
ECYT: 2.98 (-0.04)

Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 76.12 (-0.15), ECYT: 2.98 (-0.04), SHPG: 198.26 (-2.34), NKTR: 19.08 (-0.17)

Endocyte (ECYT) Reports a Narrower Q1 Loss
Ekta Bagri - Zacks Investment Research - Wed May 04, 7:53AM CDT
Endocyte reported a loss per share of 24 cents per share while our consensus called for a loss of 26 cents per share
ECYT: 2.98 (-0.04)

Endocyte reports 1Q loss
Automated Insights - Wed May 04, 7:22AM CDT
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $10.9 million in its first quarter.
ECYT: 2.98 (-0.04)

Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More
Zacks Equity Research - Zacks Investment Research - Tue May 03, 8:08AM CDT
How will biotech stocks Regeneron, Ligand, Ionis and others fare in the first quarter of 2016?
RDUS: 56.39 (+1.27), ECYT: 2.98 (-0.04), CLDX: 3.65 (-0.05), LGND: 115.54 (+0.46), AMGN: 173.52 (+0.56), IONS: 32.21 (+0.46), REGN: 408.63 (+5.88)

Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:20AM CDT
Endocyte, Inc. (ECYT) is slated to report first-quarter 2016 results on May 4.
IPXL: 26.15 (+0.27), ECYT: 2.98 (-0.04), JAZZ: 126.04 (-1.77), XON: 28.33 (+0.48)

Endocyte Announces First Quarter 2016 Earnings Conference Call
GlobeNewswire - Wed Apr 27, 3:01PM CDT
Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 4th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
ECYT: 2.98 (-0.04)

Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:01AM CDT
-- Poster demonstrates novel approach to a universal T cell overcoming key challenges of current chimeric antigen receptor (CAR) technologies/therapies
ECYT: 2.98 (-0.04)

Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Mon Apr 11, 3:01PM CDT
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
ECYT: 2.98 (-0.04)

BUYINS.NET: SOXL, AMRC, GDOT, SCHC, ECYT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Feb 04, 6:31AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Direxion Daily Semiconductor Bull 3X Shares (NYSE:SOXL), Ameresco Inc (NYSE:AMRC), Green Dot Corp (NYSE:GDOT), Schwab US Large Cap Etf (NYSE:SCHC), ENDOCYTE INC (NASDAQ:ECYT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AMRC: 5.05 (+0.10), ECYT: 2.98 (-0.04), GDOT: 22.83 (-0.26), SOXL: 42.72 (+0.02), SCHC: 30.00 (-0.22)

Valeant to Up Incentives to Retain Key Employees Amid Turmoil
Zacks Equity Research - Zacks Investment Research - Fri Nov 20, 11:50AM CST
Valeant Pharmaceuticals (VRX) is planning to offer cash and incentives to important employees in the U.S. to retain them amid the current turmoil.
ECYT: 2.98 (-0.04), VRX: 27.54 (+0.26), NVO: 46.44 (+0.32), LLY: 78.80 (-0.02)

Endocyte (ECYT) Shows Strength: Stock Moves Up 11.5%
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 7:15AM CST
Endocyte, Inc. (ECYT) shares rise over 11% in the last trading session.
ECYT: 2.98 (-0.04), CXRX: 5.40 (unch)

Endocyte (ECYT) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 11:10AM CST
Endocyte's (ECYT) Q3 loss was narrower than expected.
ESPR: 11.22 (-0.02), ECYT: 2.98 (-0.04), MRK: 62.52 (+0.24), SPPI: 4.82 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....